Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Beth Israel Deaconess Medical Center

Sites in Boston, MA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 12:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
618
Shown on this page
12
Current sort
Recently updated
Campus scope
Beth Israel Deaconess Medical Center, Boston, MA
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Beth Israel Deaconess Medical Center, Boston, MA. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 121–132 of 618 matching trials with a site at Beth Israel Deaconess Medical Center, Boston, MA.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting No phase listed Observational Accepts healthy volunteers

Brain Age and Sleep Architecture in Meditators

NCT05513846
Site status not listed — check the official record
View directory record Official record
Conditions
Brain Age
Interventions
DREEM EEG Device, SleepImage Ring
Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 19, 2026, 12:01 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

CEReBral AutorEgulation in Non-cardiac SuRgery and Relationship to Postoperative DeliriUm State

NCT06133842
Status at this site: Recruiting
View directory record Official record
Conditions
Perioperative/Postoperative Complications, Postoperative Cognitive Dysfunction, Postoperative Delirium, EEG With Periodic Abnormalities, Intraoperative Hypotension, Cerebral Hypoperfusion
Interventions
Intra-op EEG and CO data collection
Diagnostic Test
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
60 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 19, 2026, 12:01 PM EDT
Recruiting Phase 2 Interventional

A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

NCT07231952
Status at this site: Recruiting
View directory record Official record
Conditions
Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma
Interventions
Pirtobrutinib, Venetoclax, Rituximab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
9
States / cities
Boston, Massachusetts • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 19, 2026, 12:01 PM EDT
Recruiting Phase 1 Interventional

A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma

NCT07192471
Status at this site: Not yet recruiting
View directory record Official record
Conditions
T-cell NHL (PTCL or CTCL)
Interventions
KK2223
Drug
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
14
States / cities
Duarte, California • Orange, California • Stanford, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 19, 2026, 12:01 PM EDT
Recruiting Not applicable Interventional

AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions

NCT06959524
Status at this site: Recruiting
View directory record Official record
Conditions
Coronary Arterial Disease (CAD), de Novo Lesions in Native Coronary Arteries
Interventions
Drug Eluting Balloon, Drug eluting stent, Plain old balloon angioplasty
Device · Procedure
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,616 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
47
States / cities
Jonesboro, Arkansas • La Jolla, California • Los Angeles, California + 39 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 19, 2026, 12:01 PM EDT
Active, not recruiting No phase listed Observational

Multicenter Symphony™ IL-6 Monitoring Sepsis ED Pilot Study

NCT07425587
Site status not listed — check the official record
View directory record Official record
Conditions
Sepsis, Septic Shock
Interventions
Not listed
Lead sponsor
Bluejay Diagnostics, Inc.
Industry
Eligibility
22 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
5
States / cities
Gainesville, Florida • Boston, Massachusetts • Winston-Salem, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 19, 2026, 12:01 PM EDT
Active, not recruiting Phase 1 Interventional

Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients

NCT03679650
Site status not listed — check the official record
View directory record Official record
Conditions
Acute Myelogenous Leukemia
Interventions
DC/AML fusion cells
Biological
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 19, 2026, 12:01 PM EDT
Recruiting Phase 2 Interventional

A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease

NCT07214571
Status at this site: Recruiting
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
S-337395, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
37
States / cities
Los Angeles, California • Modesto, California • Toluca Lake, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 19, 2026, 12:01 PM EDT
Active, not recruiting Phase 2 Interventional

DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission

NCT03059485
Site status not listed — check the official record
View directory record Official record
Conditions
Acute Myelogenous Leukemia
Interventions
DC/AML Fusion Vaccine, Observation
Biological · Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
4
States / cities
Boston, Massachusetts • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 19, 2026, 12:01 PM EDT
Active, not recruiting Phase 1 Interventional Results available

Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations

NCT03842228
Site status not listed — check the official record
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Copanlisib Hydrochloride, Durvalumab, Echocardiography Test, Magnetic Resonance Imaging, Olaparib, X-Ray Imaging
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
17
States / cities
Buena Park, California • Los Angeles, California • Newport Beach, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 19, 2026, 12:01 PM EDT
Recruiting Not applicable Interventional

Treatment in Thoracic Aortic Aneurysm: Surgery vs Surveillance

NCT03536312
Status at this site: Recruiting
View directory record Official record
Conditions
Ascending Aortic Aneurysm Enlargement, Ascending Aorta Aneurysm
Interventions
Thoracic Aortic Surgery
Procedure
Lead sponsor
Ottawa Heart Institute Research Corporation
Other
Eligibility
18 Years to 79 Years
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2035
U.S. locations
16
States / cities
San Francisco, California • Iowa City, Iowa • Boston, Massachusetts + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 19, 2026, 12:01 PM EDT
Recruiting Not applicable Interventional

EFS of the DUO System for Tricuspid Regurgitation

NCT05913908
Status at this site: Recruiting
View directory record Official record
Conditions
Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease, Heart Valve Diseases
Interventions
DUO Transcatheter Tricuspid Coaptation Valve System
Device
Lead sponsor
CroiValve Limited
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
13
States / cities
Phoenix, Arizona • Thousand Oaks, California • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 19, 2026, 12:01 PM EDT

About this Beth Israel Deaconess Medical Center institution page

What this page lists
ClinicalTrials.gov records that list Beth Israel Deaconess Medical Center in Boston, MA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.